Payne D J, Holmes D J, Rosenberg M
Antimicrobials and Host Defense (UPI 345), GlaxoSmithKline, Collegeville, PA 19426-0989, USA.
Curr Opin Investig Drugs. 2001 Aug;2(8):1028-34.
Recent advances in DNA sequencing technology have made it possible to elucidate the sequences of the entire genomes of pathogenic bacteria and concomitant advancements in bioinformatic tools have driven comparative studies of these genome sequences. These evaluations are significantly increasing our ability to make valid considerations of the limitations and advantages of particular targets based on their predicted spectrum and selectivity. In addition, developments in gene-essentiality technologies amenable to pathogenic organisms liave enabled new genes and gene products critical to bacterial growth and pathogenicity to be uncovered at an unprecedented rate. This review will describe how aspects of the above capabilities are impacting the discovery and characterization of known and novel antibacterial targets using specific examples taken from a variety of important, diverse bacterial processes.
DNA测序技术的最新进展使得阐明致病细菌的全基因组序列成为可能，同时生物信息学工具的进步推动了对这些基因组序列的比较研究。这些评估显著提高了我们基于特定靶点的预测谱和选择性，对其局限性和优势进行有效考量的能力。此外，适用于致病生物的基因必需性技术的发展，使得对细菌生长和致病性至关重要的新基因和基因产物以前所未有的速度被发现。本综述将通过从各种重要且多样的细菌过程中选取的具体例子，描述上述能力的各个方面如何影响已知和新型抗菌靶点的发现与表征。
